{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:00:11Z","timestamp":1791039611355,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drup.2026.101440","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:05:52Z","timestamp":1782803152000},"page":"101440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling"],"prefix":"10.1016","volume":"88","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhuo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101440_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer journal clinicians"},{"key":"10.1016\/j.drup.2026.101440_bib2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41467-025-68108-2","article-title":"Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial","volume":"17","author":"Chen","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101440_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00432-022-03978-3","article-title":"Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer","volume":"149","author":"Du","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101440_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-024-07195-3","article-title":"DKK1+ tumor cells inhibited the infiltration of CCL19+ fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma","volume":"15","author":"Fan","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.drup.2026.101440_bib5","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1212\/WNL.0000000000012698","article-title":"Multicenter validation of a deep learning detection algorithm for focal cortical dysplasia","volume":"97","author":"Gill","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.drup.2026.101440_bib6","first-page":"140","article-title":"Longitudinal imaging of T cells and inflammatory demyelination in a preclinical model of multiple sclerosis using (18)F-FAraG PET and MRI","volume":"63","author":"Guglielmetti","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.drup.2026.101440_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41580-024-00768-2","article-title":"Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics","volume":"26","author":"Gulati","year":"2025","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.drup.2026.101440_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-024-08328-6","article-title":"Accurate predictions on small data with a tabular foundation model","volume":"637","author":"Hollmann","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101440_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/eus.0000000000000163","article-title":"Efficacy and diagnostic yield of 19G versus 22G fine needle biopsy needles in EUS-guided liver biopsy: a systematic review and meta-analysis","volume":"14","author":"Kalsi","year":"2025","journal-title":"Endosc. Ultrasound"},{"key":"10.1016\/j.drup.2026.101440_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jth.14642","article-title":"Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis","volume":"18","author":"Keshari","year":"2020","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.drup.2026.101440_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101440_bib15","series-title":"Proceedings of the 31st International Conference on Neural Information Processing Systems","first-page":"5115","article-title":"Regularizing deep neural networks by noise: its interpretation and optimization","author":"Noh","year":"2017"},{"key":"10.1016\/j.drup.2026.101440_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101440_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101440_bib18","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/cam4.2748","article-title":"Breast cancer stromal clotting activation (Tissue Factor and thrombin): a pre-invasive phenomena that is prognostic in invasion","volume":"9","author":"Shaker","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101440_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","article-title":"The advent of immune stimulating CAFs in cancer","volume":"23","author":"Tsoumakidou","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.drup.2026.101440_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011648","article-title":"FMO2(+) cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma","volume":"13","author":"Xu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.21037\/hbsn-21-288","article-title":"Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study","volume":"12","author":"Yan","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.drup.2026.101440_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-025-02314-w","article-title":"Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response","volume":"24","author":"Zeng","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101440_bib24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.21037\/hbsn-24-175","article-title":"Neoadjuvant systemic therapy for hepatocellular carcinoma: challenges and opportunities-a narrative review","volume":"14","author":"Zhang","year":"2025","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.drup.2026.101440_bib25","doi-asserted-by":"crossref","DOI":"10.34133\/research.0950","article-title":"POSTN(+) CAF-derived migrasomes drive hepatocellular carcinoma progression and confer resistance to immunotherapy","volume":"8","author":"Zhu","year":"2025","journal-title":"Research"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:48:22Z","timestamp":1784836102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S1368764626000919"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101440","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101440"}}